Loading clinical trials...
Loading clinical trials...
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INV-101 Administered Orally to Healthy Adult Subjects
Conditions
Interventions
INV-101
Locations
1
South Korea
Innovo Therapeutics, Inc.
Seoul, South Korea
Start Date
April 21, 2022
Primary Completion Date
July 16, 2022
Completion Date
August 31, 2022
Last Updated
May 6, 2023
NCT07271069
NCT06975722
NCT07185009
NCT07184996
NCT07245394
NCT07089420
Lead Sponsor
Innovo Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions